bluebird bio (BLUE) said Tuesday that it is launching a restructuring plan to reduce its workforce by 25%.
The company said the layoffs and other measures will bring it to quarterly cash flow break-even in H2 of next year and reduce cash operating expenses by 20% in Q3 of next year.
Chief Executive Andrew Obenshain said the restructuring will help the gene therapy company attract more investment.
Price: 0.5062, Change: +0.02, Percent Change: +3.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.